Additionally, blocking FASN with EGCG has been found to significantly ameliorate the efficacy of cetuximab and pertuzumab in drug-resistant breast cancer, suggesting EGCG may synergize the antitumor effects of anti-EGFR and anti-HER2 therapies (226, 227). The gene discussed is ERBB2; the disease is breast cancer.